Cargando…

Overall and disease‐specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer

BACKGROUND: Hodgkin lymphoma (HL) survivors have an increased risk of gastrointestinal (GI) cancer. This study aims to evaluate whether survival of patients who survived HL and developed GI cancer differs from survival of first primary GI cancer patients. METHODS: Overall and cause‐specific survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Rigter, Lisanne S., Schaapveld, Michael, Janus, Cecile P. M., Krol, Augustinus D. G., van der Maazen, Richard W. M., Roesink, Judith, Zijlstra, Josee M., van Imhoff, Gustaaf W., Poortmans, Philip M. P., Beijert, Max, Lugtenburg, Pieternella J., Visser, Otto, Snaebjornsson, Petur, van Eggermond, Anna M., Aleman, Berthe M. P., van Leeuwen, Flora E., van Leerdam, Monique E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346242/
https://www.ncbi.nlm.nih.gov/pubmed/30592184
http://dx.doi.org/10.1002/cam4.1922
_version_ 1783389725706420224
author Rigter, Lisanne S.
Schaapveld, Michael
Janus, Cecile P. M.
Krol, Augustinus D. G.
van der Maazen, Richard W. M.
Roesink, Judith
Zijlstra, Josee M.
van Imhoff, Gustaaf W.
Poortmans, Philip M. P.
Beijert, Max
Lugtenburg, Pieternella J.
Visser, Otto
Snaebjornsson, Petur
van Eggermond, Anna M.
Aleman, Berthe M. P.
van Leeuwen, Flora E.
van Leerdam, Monique E.
author_facet Rigter, Lisanne S.
Schaapveld, Michael
Janus, Cecile P. M.
Krol, Augustinus D. G.
van der Maazen, Richard W. M.
Roesink, Judith
Zijlstra, Josee M.
van Imhoff, Gustaaf W.
Poortmans, Philip M. P.
Beijert, Max
Lugtenburg, Pieternella J.
Visser, Otto
Snaebjornsson, Petur
van Eggermond, Anna M.
Aleman, Berthe M. P.
van Leeuwen, Flora E.
van Leerdam, Monique E.
author_sort Rigter, Lisanne S.
collection PubMed
description BACKGROUND: Hodgkin lymphoma (HL) survivors have an increased risk of gastrointestinal (GI) cancer. This study aims to evaluate whether survival of patients who survived HL and developed GI cancer differs from survival of first primary GI cancer patients. METHODS: Overall and cause‐specific survival of GI cancer patients in a HL survivor cohort (GI‐HL, N = 104, including esophageal, gastric, small intestinal, and colorectal cancer) was compared with survival of a first primary GI cancer patient cohort (GI‐1, N = 1025, generated by case matching based on tumor site, gender, age, and year of diagnosis). Cox proportional hazards regression was used for survival analyses. Multivariable analyses were adjusted for GI cancer stage, grade of differentiation, surgery, radiotherapy, and chemotherapy. RESULTS: GI‐HL cancers were diagnosed at a median age of 54 years (interquartile range 45‐60). No differences in tumor stage or frequency of surgery were found. GI‐HL patients less often received radiotherapy (8% vs 23% in GI‐1 patients, P < 0.001) and chemotherapy (28% vs 41%, P = 0.01) for their GI tumor. Compared with GI‐1 patients, overall and disease‐specific survival of GI‐HL patients was worse (univariable hazard ratio (HR) 1.30, 95% confidence interval (CI) 1.03‐1.65, P = 0.03; and HR 1.29, 95% CI 1.00‐1.67, P = 0.049, respectively; multivariable HR 1.33, 95% CI 1.05‐1.68, P = 0.02; and HR 1.33, 95% CI 1.03‐1.72, P = 0.03, respectively). CONCLUSIONS: Long‐term overall and disease‐specific survival of GI cancer in HL survivors is worse compared with first primary GI cancer patients. Differences in tumor stage, grade of differentiation, or treatment could not explain this worse survival.
format Online
Article
Text
id pubmed-6346242
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-63462422019-01-29 Overall and disease‐specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer Rigter, Lisanne S. Schaapveld, Michael Janus, Cecile P. M. Krol, Augustinus D. G. van der Maazen, Richard W. M. Roesink, Judith Zijlstra, Josee M. van Imhoff, Gustaaf W. Poortmans, Philip M. P. Beijert, Max Lugtenburg, Pieternella J. Visser, Otto Snaebjornsson, Petur van Eggermond, Anna M. Aleman, Berthe M. P. van Leeuwen, Flora E. van Leerdam, Monique E. Cancer Med Clinical Cancer Research BACKGROUND: Hodgkin lymphoma (HL) survivors have an increased risk of gastrointestinal (GI) cancer. This study aims to evaluate whether survival of patients who survived HL and developed GI cancer differs from survival of first primary GI cancer patients. METHODS: Overall and cause‐specific survival of GI cancer patients in a HL survivor cohort (GI‐HL, N = 104, including esophageal, gastric, small intestinal, and colorectal cancer) was compared with survival of a first primary GI cancer patient cohort (GI‐1, N = 1025, generated by case matching based on tumor site, gender, age, and year of diagnosis). Cox proportional hazards regression was used for survival analyses. Multivariable analyses were adjusted for GI cancer stage, grade of differentiation, surgery, radiotherapy, and chemotherapy. RESULTS: GI‐HL cancers were diagnosed at a median age of 54 years (interquartile range 45‐60). No differences in tumor stage or frequency of surgery were found. GI‐HL patients less often received radiotherapy (8% vs 23% in GI‐1 patients, P < 0.001) and chemotherapy (28% vs 41%, P = 0.01) for their GI tumor. Compared with GI‐1 patients, overall and disease‐specific survival of GI‐HL patients was worse (univariable hazard ratio (HR) 1.30, 95% confidence interval (CI) 1.03‐1.65, P = 0.03; and HR 1.29, 95% CI 1.00‐1.67, P = 0.049, respectively; multivariable HR 1.33, 95% CI 1.05‐1.68, P = 0.02; and HR 1.33, 95% CI 1.03‐1.72, P = 0.03, respectively). CONCLUSIONS: Long‐term overall and disease‐specific survival of GI cancer in HL survivors is worse compared with first primary GI cancer patients. Differences in tumor stage, grade of differentiation, or treatment could not explain this worse survival. John Wiley and Sons Inc. 2018-12-27 /pmc/articles/PMC6346242/ /pubmed/30592184 http://dx.doi.org/10.1002/cam4.1922 Text en © 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Rigter, Lisanne S.
Schaapveld, Michael
Janus, Cecile P. M.
Krol, Augustinus D. G.
van der Maazen, Richard W. M.
Roesink, Judith
Zijlstra, Josee M.
van Imhoff, Gustaaf W.
Poortmans, Philip M. P.
Beijert, Max
Lugtenburg, Pieternella J.
Visser, Otto
Snaebjornsson, Petur
van Eggermond, Anna M.
Aleman, Berthe M. P.
van Leeuwen, Flora E.
van Leerdam, Monique E.
Overall and disease‐specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer
title Overall and disease‐specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer
title_full Overall and disease‐specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer
title_fullStr Overall and disease‐specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer
title_full_unstemmed Overall and disease‐specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer
title_short Overall and disease‐specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer
title_sort overall and disease‐specific survival of hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346242/
https://www.ncbi.nlm.nih.gov/pubmed/30592184
http://dx.doi.org/10.1002/cam4.1922
work_keys_str_mv AT rigterlisannes overallanddiseasespecificsurvivalofhodgkinlymphomasurvivorswhosubsequentlydevelopedgastrointestinalcancer
AT schaapveldmichael overallanddiseasespecificsurvivalofhodgkinlymphomasurvivorswhosubsequentlydevelopedgastrointestinalcancer
AT januscecilepm overallanddiseasespecificsurvivalofhodgkinlymphomasurvivorswhosubsequentlydevelopedgastrointestinalcancer
AT krolaugustinusdg overallanddiseasespecificsurvivalofhodgkinlymphomasurvivorswhosubsequentlydevelopedgastrointestinalcancer
AT vandermaazenrichardwm overallanddiseasespecificsurvivalofhodgkinlymphomasurvivorswhosubsequentlydevelopedgastrointestinalcancer
AT roesinkjudith overallanddiseasespecificsurvivalofhodgkinlymphomasurvivorswhosubsequentlydevelopedgastrointestinalcancer
AT zijlstrajoseem overallanddiseasespecificsurvivalofhodgkinlymphomasurvivorswhosubsequentlydevelopedgastrointestinalcancer
AT vanimhoffgustaafw overallanddiseasespecificsurvivalofhodgkinlymphomasurvivorswhosubsequentlydevelopedgastrointestinalcancer
AT poortmansphilipmp overallanddiseasespecificsurvivalofhodgkinlymphomasurvivorswhosubsequentlydevelopedgastrointestinalcancer
AT beijertmax overallanddiseasespecificsurvivalofhodgkinlymphomasurvivorswhosubsequentlydevelopedgastrointestinalcancer
AT lugtenburgpieternellaj overallanddiseasespecificsurvivalofhodgkinlymphomasurvivorswhosubsequentlydevelopedgastrointestinalcancer
AT visserotto overallanddiseasespecificsurvivalofhodgkinlymphomasurvivorswhosubsequentlydevelopedgastrointestinalcancer
AT snaebjornssonpetur overallanddiseasespecificsurvivalofhodgkinlymphomasurvivorswhosubsequentlydevelopedgastrointestinalcancer
AT vaneggermondannam overallanddiseasespecificsurvivalofhodgkinlymphomasurvivorswhosubsequentlydevelopedgastrointestinalcancer
AT alemanberthemp overallanddiseasespecificsurvivalofhodgkinlymphomasurvivorswhosubsequentlydevelopedgastrointestinalcancer
AT vanleeuwenflorae overallanddiseasespecificsurvivalofhodgkinlymphomasurvivorswhosubsequentlydevelopedgastrointestinalcancer
AT vanleerdammoniquee overallanddiseasespecificsurvivalofhodgkinlymphomasurvivorswhosubsequentlydevelopedgastrointestinalcancer